Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US11091505B2 · kind B2 · utility
2Cited by
10References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2018 |
| Grant date | Aug 17, 2021 |
| Priority date | — |
| Expiry date | Mar 5, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/546
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.